Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYL719 with Chemoradiotherapy in Head and Neck Cancer
NCT02537223Phase 1Completed
- Sponsor
- University Health Network
- Start
- Sep 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpelisib in head and neck squamous cell carcinoma (HNSCC), sponsored by University Health Network. Primary endpoint: Number of Treatment Emergent Side Effects at 3 years. Started Sep 2015; status: completed.
02
Drugs
alpelisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02537223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537223.